Leukemia author guidelines

Manuscripts can be directly submitted to leukemia@somatopublications.com along with the cover letter with the special issue title. Submitted manuscripts will be handled by guest editor for further peer review. Authors are instructed to follow the Author Guidelines before submission of manuscript to any of the special issues. Author guidelines General standards Article type. Frontiers requires authors to select the appropriate article type for their manuscript and to comply with the article type descriptions defined in the journal's 'Article types' page, which can be seen from the 'For authors' menu on every Frontiers journal page. Please pay close attention to the Leukemia Research is an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies. The Journal scope includes reporting studies of Author Guidelines. Authors are instructed to follow the guidelines before submission of manuscript to Annals of Leukemia Research. Peer Review : Annals of Leukemia Research follows double blinded peer review process where authors and reviewers donot know the identities of each other and kept confidential. Publication Ethics : Articles published under Annals of Leukemia Research follow COPE-Community of Publication Ethics. Authors Patrick A Brown 1 , Bijal Shah 2 , Anjali Advani 3 , Patricia Aoun 4 , Michael W Boyer 5 The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies Diagnosis and Staging. All three guidelines are in agreement that the diagnosis of CLL requires the presence of ≥5 × 10 9 /L B-lymphocytes in the peripheral blood and the clonality of the circulating B lymphocytes should be confirmed by flow cytometry. The IWCLL guidelines also require persistence of lymphocytosis for longer than 3 months, while NCCN and ESMO do not. During the past 10 years, significant progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options in chronic lymphocytic leukemia (CLL). These developments have led to revision of the National Cancer Institute-sponsored Working Group (NCI-WG) guidelines on CLL established in 1988 and 1996. The Society for Immunotherapy of Cancer (SITC) published it's first clinical practice guideline (CPG) on immunotherapy for the treatment of Acute Leukemia in the Journal for ImmunoTherapy of Cancer on October 19, 2020. SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as Lancet Infectious Diseases 2019, doi: 10.1016/s1473-3099 (18)30600-5. Guidelines from the 2017 European Conference on Infections in Leukemia for management of HHV-6 infection in patients with hematological malignancies and after hematopoietic stem cell transplantation. Ward KN, Hill JA, Hubacek P, de la Camara R, Crocchiolo R, Einsele H Author names should be " [Last name] [space] [first initial] [middle initial (optional)]", such as: " Smith JH " for "John Henry Smith"; " Doe J " for "Jane Doe". Author names are separated by comma. If there are up to 6 authors, list all au